Background: Pseudomonas aeruginosa is a common cause of hospital-acquired infections. Carbapenems are β-lactam antibiotics with a wide-ranging antibacterial effect. Carbapenems are the most dependable last option for treating infections generated by multidrug-resistant pathogens Carbapenem resistant P. aeruginosa (CRPA) isolates are increasingly observed. has emerged as a prominent global public health issue. Aim of the work: To detect the presence of carbapenem resistant P. aeruginosa in different wards of Minia University hospitals. Methods: From August 2022 to January 2023 carbapenem resistant P. aeruginosa was isolated from different clinical specimen received to clinical microbiology unit, minia university hospital. And the minimal inhibitory concentration of meropenem & imipenem were detected by VITEK-2.Results: 167 P. aeruginosa isolates were recovered. CRPA were 45 isolates (26.9 %). Most of CRPA isolated from patients of ICUs (55.8%) and the urine specimens were the highest specimen from which CRPA isolated. Conclusion: high level of carpabenem resistance among P. aeruginosa in our medical setting.
No takes yet. Share an insight, caveat, or question.
Ali et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: